Company Overview - CorMedix Therapeutics is a diversified specialty pharmaceutical company focused on institutional settings of care, primarily offering injectable drugs used in hospitals and infusion centers [3] - The company has a strong financial profile with approximately $150 million in cash and close to zero net debt [3] Financial Projections - Revenue guidance for 2026 is projected to exceed $300 million, with EBITDA expected to be between $100 million and $125 million [3] - The company anticipates increasing its cash position throughout the year [3] Commercial Strategy - CorMedix has a scalable platform supported by a solid commercial team experienced across multiple therapeutic areas [4]

Core Viewpoint - ROVI has announced the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona, which is expected to enhance its production capabilities and strategic positioning in the market [1]. Group 1: Acquisition Details - The acquisition involves a manufacturing site that will support ROVI's injectable drug product line, indicating a strategic move to bolster its operational capacity [1]. - The call includes insights from ROVI's Chairman and CEO, Juan Lopez-Belmonte, and Deputy Chairman and CFO, Javier Lopez-Belmonte, who will elaborate on the strategic rationale and key terms of the transaction [1]. Group 2: Presentation Logistics - A presentation deck related to the acquisition is available in the Investors section of ROVI's website, which will be discussed during the conference call [2]. - The call will include a Q&A session, encouraging participants to submit questions throughout the presentation [2]. Group 3: Forward-Looking Statements - The company acknowledges that some statements made during the call may be forward-looking and are based on current beliefs and expectations, with actual results potentially differing due to various risks and uncertainties [3].